$XOMAO

Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation (HoldCo) as a party, making HoldCo a wholly owned subsidiary of Ligand after the merger. This amendment follows Ligand's strong financial performance, including a 104% return over the past year, despite a recent Q1 2026 earnings miss. The transaction is contingent on regulatory and XOMA Royalty stockholder approvals.

BVF group entities converted 5,003 shares of XOMA Royalty Corp's Series X Convertible Preferred Stock into 5,003,000 shares of common stock at $4.03 per share on May 14, 2026. This transaction changed the form of ownership from preferred to common stock for the reporting group, which is a Section 13(d) group owning over 10% of XOMA common stock. The conversions are exempt from short-swing profit rules under Rule 16b-6(b).

XOMA Royalty Corporation announced that its CFO, Thomas Burns, is stepping down after nearly two decades with the company to pursue other professional opportunities. Jeffrey Trigilio, formerly of Obsidian Therapeutics and Cullinan Therapeutics, has been appointed as the new CFO. XOMA Royalty specializes in acquiring future economics of therapeutic candidates and has seen its shares rise significantly over the past year.